AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$INCY

CAGNONI PABLO J sold $2.8M of INCY

CAGNONI PABLO J (President, Global Head of R&D) sold 23,218 shares of INCYTE CORP (INCY) at an average of $120.49 ($120.49–$120.50, $2.80M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAGNONI PABLO J
Published Sep 17, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
medium confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

Provides transparency but limited trading relevance for the stock.

02

Market read

Minor insider sale with modest dollar value; unlikely to move the market.

03

What to watch

Potential upcoming R&D milestones not disclosed.

Relevance 5/10Novelty 4/10Timing: filed Sep 17 2026

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$INCYNeutralMedium confidence
Context

President Pablo Cagnoni sold 23,218 shares for $2.8M via a 10b5‑1 plan.

Expected impact

Limited short‑term impact; possible slight downward pressure.

Evidence & confidence

Sale amount is under 1% of float and follows a pre‑arranged plan, reducing informational value.

Market effects

Sector

No broader sector impact; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be a routine liquidity event, not a negative signal.

Key entities

  • Insider
    Pablo Cagnoni

    President, Global Head of R&D at Incitec Pivot.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INCY insider trading history →

Related articles

OCT 13
Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

tradingview.com1 min
OCT 13
$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

pharmaphorum.com2 min
OCT 7
$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.

simplywall.st2 min